Loading
Tick Borne Diseases · Journal article
Emerging Microbes & Infections · September 12, 2026
Encouraging direction, but not yet definitive.
This study reports development and validation of a multiplex qPCR panel detecting 25 tick-borne pathogens across 8 assays, with analytically robust performance (96.5% sensitivity and specificity, AUC 0.979) established via nested PCR sequencing and digital PCR standards. Application to clinical and surveillance specimens identified diverse pathogen prevalence: 16.9% of ticks, 7.9% of acute febrile illness patients (including SFTSV and Ehrlichia), and predominantly Bartonella in rodents, positioning the panel as a high-throughput diagnostic and epidemiological tool.
Diagnostic validation and multi-host surveillance study. Ticks (n=2,333; species not specified), rodents (n=59; species not specified), and febrile patients (n=553; n=317 acute febrile illness, fever of unknown origin cohort size not specified) from unspecified geographic setting(s); patient age, sex, and clinical characteristics not detailed. Intervention: Eight-assay multiplex qPCR panel for simultaneous detection of 25 tick-borne pathogens (7 bacteria, 14 viruses, 4 parasites). Compared with: Nested/semi-nested PCR amplicon sequencing and digital PCR as analytical reference standards for Cq cut-off optimization. n = 2,945. Not explicitly stated; inferred multi-region surveillance from mention of 'diverse geographical distribution' in tick findings, but specific countries, regions, or number of sites not reported.
Panel detected 25 tick-borne pathogens (7 bacteria, 14 viruses, 4 parasites) across 8 multiplex qPCR assays Analytical performance: 96.5% sensitivity, 96.5% specificity, AUC 0.979 with tiered Cq determination framework Pathogen prevalence in 2,333 ticks: 16.9% (395/2,333) carried 14 different pathogens with diverse geographical distribution
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This validated panel offers clinicians and epidemiologists a rapid, high-throughput diagnostic tool to identify tick-borne pathogen etiology in undifferentiated febrile illness and to conduct surveillance of circulating pathogens in reservoir and vector populations. The strong analytical performance and discovery of co-circulating pathogens including SFTSV and Ehrlichia in symptomatic patients supports clinical adoption for differential diagnosis where tick-borne disease is in the differential, though clinical outcome data (treatment impact, prognosis) are not provided.
A rigorously validated multiplex diagnostic panel with strong analytical performance (96.5% sensitivity/specificity, AUC 0.979) applied to clinical and epidemiological surveillance, but representing a diagnostic tool validation and descriptive screening study rather than a clinical outcome trial.
As stated by the source record.
Quoted from the source exactly as published.
This validated panel offers clinicians and epidemiologists a rapid, high-throughput diagnostic tool to identify tick-borne pathogen etiology in undifferentiated febrile illness and to conduct surveillance of circulating pathogens in reservoir and vector populations. The strong analytical performance and discovery of co-circulating pathogens including SFTSV and Ehrlichia in symptomatic patients supports clinical adoption for differential diagnosis where tick-borne disease is in the differential, though clinical outcome data (treatment impact, prognosis) are not provided.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Tick-borne diseases pose significant public health threats. Non-specific symptoms and co-infections present diagnostic challenges for conventional methods. To address this, we developed the tick-borne pathogen (TBP) Panel, utilizing eight separate multiplex qPCR assays to simultaneously detect 25 TBPs (7 bacteria, 14 viruses, 4 parasites). Optimal Quantification Cycle (Cq) cut-offs were established using nested/semi-nested PCR amplicon sequencing, and digital PCR as reference standards. The Panel was then deployed for screening 2,333 ticks, 59 rodents, and 553 febrile patients. The Panel demonstrated robust analytical performance, achieving limits of detection (LOD99%) being 3.5-131 copies/reaction of plasmid, 102-103 copies/mL of blood and 103-104 copies/tick pool. This study established a tiered determination framework (Cq ≤ 36.6 as positive; Cq 36.6-39.6 requiring dual-replicate confirmation), yielding an overall AUC of 0.979, with 96.5% sensitivity and 96.5% specificity. Screening revealed a diverse pathogen landscape, identifying a total of 14 pathogens in 16.9% of the ticks (395/2,333), revealing a diverse geographical distribution. Five pathogens were identified in 7.9% of AFI patients (25/317), including Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) and Ehrlichia spp., which were found circulating in local ticks. In the FUO cohort, a single case of Rickettsia spp. was identified. Rodent surveillance identified four pathogens, predominantly Bartonella spp. (67.8%). In conclusion, the rigorously validated TBP Panel enables rapid etiological identification of undifferentiated febrile illnesses, serving as a high-throughput tool that bridges large-scale surveillance with clinical diagnostics to close critical gaps in tick-borne disease management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.